|This retrospective study investigated a population of 96 dogs with newly diagnosed malignant lymphosarcoma that were treated with the commonly used University of Wisconsin-Madison (UW-M) chemotherapy protocol.
Pretreatment characteristics were analyzed to determine prognostic factors.
Dogs with higher World Health Organization (WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher risk of relapse (P=0.018 and P=0.016, respectively).
Dose reduction, treatment delays, and prior therapy with cortico-steroids were not associated with clinical outcome.
First remission duration of 270 days was similar to historically reported data.
Overall survival time of 218 days was much shorter than historical data.
Source: Claire Inderbinen Kaiser, Janean L. Fidel, Malgorzata Roos, Barbara Kaser-Hotz (2007): Reevaluation of the University of Wisconsin 2-Year Protocol for Treating Canine Lymphosarcoma. In: Journal of the American Animal Hospital Association 43:85-92 (2007)
Tell a friend
Send this article